导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.36% | 3298/4773 |
| 近一周 | -2.74% | 4634/5467 |
| 近一月 | -4.14% | 1559/5421 |
| 近一季 | -3.30% | 1394/5238 |
| 近半年 | -5.66% | 3165/4931 |
| 近一年 | -6.39% | 3183/4400 |
| 近两年 | 27.11% | 2392/2954 |
| 近三年 | 8.04% | 1788/2253 |
| 成立以来 | 187.20% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.16% 3060/4961 |
1.43% 3024/5312 |
- - |
- - |
| 2025 | 7.73% 2916/4813 |
-0.80% 2412/3635 |
-2.46% 3356/4076 |
14.80% 2872/4524 |
-3.02% 3243/4813 |
| 2024 | 14.14% 1071/3463 |
3.85% 505/2808 |
-2.59% 1208/3014 |
19.96% 783/3129 |
-5.95% 2612/3463 |
| 2023 | -6.93% 884/2656 |
5.02% 841/2280 |
-5.02% 1342/2385 |
0.70% 352/2515 |
-7.34% 2121/2655 |
| 2022 | -18.04% 654/2207 |
-10.33% 391/1919 |
1.96% 1392/2016 |
-12.66% 755/2113 |
2.65% 871/2208 |
| 2021 | -4.67% 957/1822 |
0.98% 267/1255 |
-1.06% 1158/1330 |
-3.68% 655/1466 |
-0.93% 1287/1822 |
| 2020 | 27.54% 577/1250 |
-13.37% 926/1028 |
12.38% 687/1067 |
12.16% 403/1164 |
16.81% 151/1184 |
| 2019 | 54.58% 75/1092 |
37.29% 76/754 |
0.09% 201/804 |
0.14% 554/850 |
12.34% 38/918 |
| 2018 | -23.43% 278/834 |
- - |
- - |
- - |
-8.98% 113/691 |
| 2017 | 45.17% 17/714 |
- - |
- - |
- - |
- - |
| 2016 | -4.45% 157/605 |
- - |
- - |
- - |
- - |
| 2015 | 18.45% 127/575 |
- - |
- - |
- - |
- - |
| 2014 | 54.88% 54/237 |
- - |
- - |
- - |
- - |
| 2013 | -7.94% 132/186 |
- - |
- - |
- - |
- - |
| 2012 | 2.43% 96/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 建信深证基本面60ETF VS. 长安沪深300非周期A(740101) |